Use of venetoclax in transplant conditioning regimen shows promise in myeloid cancers
(PHYSorg.com Medicine & Health)

For patients with high-risk myeloid cancers undergoing a donor stem cell transplant, adding the targeted drug venetoclax to a reduced-intensity drug regimen prior to transplant is safe and does not impair the ability of the donor cells to take root in recipients` bodies, a study led by Dana-Farber Cancer Institute researchers suggests. The study will be presented today at the 61st American Society of Hematology (ASH) Annual Meeting.